Of the handful of companies conducting clinical trials on cannabinoids, AXIM® Biotechnologies (OTC: AXIM), which was recently featured in Fox Business, has positioned itself as one to watch. Founded in 2010, innovative biotechnology company AXIM Biotech has set the standard for cannabinoid bioscience through the discovery and commercialization of cannabinoid-based pharmaceuticals and supplements.
With AXIM Biotech’s pioneering patents, its innovative pipeline of products and clinical trials, and proven executive management team, this company has set the stage for significant growth over the coming year.
Important Patent Innovations
This past November, AXIM Biotechnologies was granted a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. The patent covers the inclusion of all cannabinoids, including tetrahydrocannabinol (THC), in a chewing gum delivery system.
AXIM Biotech had already held the exclusive rights to the world’s first patented cannabinoid release chewing gum, CanChew® Plus, which